

DESCRIPTION

Source *E. coli*-derived
His25-Ser153, with an N-terminal Met
Accession # P51492

N-terminal Sequence Analysis Met

Predicted Molecular Mass 15.1 kDa

SPECIFICATIONS

Activity Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. Kitamura, T. *et al.* (1989) *J. Cell Physiol.* **140**:323. The ED₅₀ for this effect is typically 0.25-1 ng/mL.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 10 µg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13 kDa - 18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1 - 3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four α -helix structure (4). Rhesus IL-4 is synthesized with a 24 amino acid (aa) signal sequence. Mature rhesus IL-4 shares 97%, 93%, and 93% aa sequence identity with baboon, chimpanzee, and human IL-4, respectively, and 39% - 50% aa sequence identity with bovine, mouse, and rat IL-4. IL-4 exerts its effects through two receptor complexes (5, 6). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R α and the common γ chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and -21). The type II receptor on nonhematopoietic cells consists of IL-4 R α and IL-13 R α 1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased CD4⁺ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgE in B cells, acquisition of the Th2 phenotype by naive CD4⁺ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (7 - 10). IL-4 plays a dominant role in the development of allergic inflammation and asthma (9, 11).

References:

1. Benczik, M. and S.L. Gaffen (2004) *Immunol. Invest.* **33**:109.
2. Chomarat, P. and J. Banchereau (1998) *Int. Rev. Immunol.* **17**:1.
3. SwissProt # P51492.
4. Redfield, C. *et al.* (1991) *Biochemistry* **30**:11029.
5. Mueller, T.D. *et al.* (2002) *Biochim. Biophys. Acta* **1592**:237.
6. Nelms, K. *et al.* (1999) *Annu. Rev. Immunol.* **17**:701.
7. Paludan, S.R. (1998) *Scand. J. Immunol.* **48**:459.
8. Corthay, A. (2006) *Scand. J. Immunol.* **64**:93.
9. Ryan, J.J. *et al.* (2007) *Crit. Rev. Immunol.* **27**:15.
10. Grone, A. (2002) *Vet. Immunol. Immunopathol.* **88**:1.
11. Rosenberg, H.F. *et al.* (2007) *J. Allergy Clin. Immunol.* **119**:1303.